ABBOTT LABORATORIES
ABBOTT LABORATORIES (ABT) Stock News
The latest ABT headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·
Abbott (ABT) Gains As Market Dips: What You Should Know
Abbott (ABT) closed at $101.82, up 2.23%, outperforming the S&P 500's 0.06% decline. The company is expected to report Q3 earnings on October 21, 2026, with projected EPS of $1.42 (up 9.23% YoY) and revenue of $12.91 billion (up 13.52% YoY). Abbott holds a Zacks Rank #2 (Buy) rating and trades at a Forward P/E of 18.04, below its industry average of 19.61.
- Zacks Investment Research·Neutral
Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Abbott stock closed down 2.1%, underperforming the S&P 500's 0.25% loss. The stock has declined 7.33% over the past month, significantly lagging the Medical sector. Upcoming earnings are expected to show $1.43 EPS (10% YoY growth) and $12.91B revenue (13.52% increase). Abbott holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.28, trading at a discount to its industry average.
- Zacks Investment Research·Neutral
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) declined 2.2% to $111.59 in the latest trading session, underperforming the S&P 500's 0.72% gain. Despite the daily decline, the company has appreciated 5.65% over the past month. Analysts project strong earnings growth with expected EPS of $1.43 (up 10% YoY) and quarterly revenue of $12.91 billion (up 13.52% YoY). Abbott holds a Zacks Rank of #3 (Hold) with a Forward P/E of 20.66, trading at a slight discount to its industry average.